123 results
D
HEPA
Hepion Pharmaceuticals Inc
3 Oct 23
$5.00 mm in equity / options, sold $5.00 mm, 1 investor
5:22pm
, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot
routinely require offering materials
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property … not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
424B5
15ovx
2 Oct 23
Prospectus supplement for primary offering
4:52pm
8-K
EX-99.1
ggj 6ygqnek3ouca67i
24 Jul 23
Regulation FD Disclosure
4:04pm
8-K
EX-1.1
ytf6pc 3ipzf3
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
424B5
u0l2btki
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.1
gp1jhp79
22 May 23
Regulation FD Disclosure
1:05pm
D
cfmc928
15 Nov 22
$20.00 mm in equity, sold $20.00 mm, 8 investors
4:14pm
8-K
EX-10.1
d58565fh853uz7
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-10.3
htj ixed2wi
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-10.2
k4jozkm4rwaha
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-99.1
bfk w5yc9jk3l
28 Jun 22
Departure of Directors or Certain Officers
9:46am